49results about How to "Enhance specific immune response" patented technology

The invention discloses an oral vaccine delivery system. W1 of W1 / O / W2 type nanoparticles is a vaccine medicine phase, an organic phase O is selected from PLGA and HP55, an external water phase W2 and a continuous water phase are selected from poloxamer 188, and a vaccine medicine is a double epitope-double adjuvant helicobacter pylori vaccine. The method adopts a polymer material having good biological safety and good compatibility to prepare the nanoparticles, a preparation process and a formula are optimized, the oral vaccine delivery system is non-toxic, free of any side effects, easy to manufacture and low in cost. In the field of biological medicines, the nanoparticles can be used for oral taking of a helicobacter pylori subunit vaccine, accordingly helicobacter pylori infection related diseases are prevented and treated, and huge economic benefits and social benefits are brought.

The invention provides a feed additive containing yeast cell polysaccharides. The feed additive is prepared from 90-95 percent of yeast cell polysaccharides, 2-6 percent of saccharomycetes, 1-3 percent of bacillus subtilis and 1-3 percent of bacillus licheniformis. The saccharomycetes, bacillus subtilis, bacillus licheniformis and yeast cell polysaccharides are compounded and matched with one another, so that the intestinal health level of piglets is improved, the body immunity is enhanced, and the antibody valence of piglet inject vaccines is improved.

The invention discloses a Haemonchus contortus nano-material subunit vaccine and applications thereof. The Haemonchus contortus nano-material subunit vaccine is a subunit vaccine prepared by wrappinghaemonchus contortus recombinant protein HCA59 with nano-material PLGA, the recombinant HCA59 protein has an amino acid sequence as shown in SEQ ID NO. 1. The subunit vaccine can be used for preventing haemonchus contortus infection of sheep. The particle size of the nano subunit vaccine is 75 to 402nm; the Haemonchus contortus nano-material subunit vaccine has good biocompatibility and unique physicochemical properties, has the advantages of targeting property, slow release property, safety, high efficiency and the like, and can be decomposed and metabolized in an animal body; the vaccine hasan irritant antigen effect of stimulating dendritic cells, can promote the capability of converting mononuclear cells into the dendritic cells, has relatively strong immunoprotection capability, andcan remarkably reduce the ovum discharge rate and adult reduction rate of goats infected with haemonchus contortus clinically.

The disclosed invention provides mammalian milk osteopontin and / or an active truncation or active peptide thereof for improving immune responsiveness to an infectious disease in a mammal, for example a human subject, as well as enhancing the efficacy of vaccination for the prophylactic or therapeutic treatment of an infectious disease in mammals, such as humans. The invention further provides a vaccine system, for use in the prophylactic or therapeutic treatment of an infectious disease in a mammal, comprising a vaccine and a mammalian milk osteopontin and / or an active truncation or active peptide thereof for oral administration to a mammal, as well as methods of enhancing immune resistance to an infectious disease in a mammal by administration of a vaccine and a mammalian milk osteopontin and / or an active truncation thereof.

The invention relates to a meningococcus vaccine comprising a chemical conjugate of meningococcus capsular polysaccharide and carrier protein, and a first adjuvant, wherein the first adjuvant is oligodeoxynucleotide comprising at least one non-methylation CpG dinucleotide, and the length of the oligodeoxynucleotide is 15-35 ribonucleotides. The adjuvant used for increasing the immunization effectof the meningococcus vaccine is a novel human vaccine adjuvant with favorable potential application prospect, and the chemical essence of the adjuvant is the oligodeoxynucleotide which is synthesizedmanually and contains the CpG dinucleotide. By a receptor TLR9 activated immune system on immune cells, the adjuvant reinforces specific immune response aiming at vaccine antigens. The immunization effect of a vaccine can be increased by adding the vaccine adjuvant into the vaccine, so that the dosage of the vaccine antigen can be reduced, the immunization injection times can be reduced and the vaccine cost can be reduced.

The invention provides a polypeptide for promoting a pig body to generate broad-spectrum immune response and application thereof, and belongs to the technical field of biomedicine. The polypeptide comprises one or more of a first polypeptide, a second polypeptide, a third polypeptide, a fourth polypeptide and a fifth polypeptide; the amino acid sequences of the first polypeptide, the second polypeptide, the third polypeptide, the fourth polypeptide and the fifth polypeptide are respectively shown as SEQ ID NO. 1 to SEQ ID NO. 5. The polypeptide provided by the invention can promote the pig body to generate broad-spectrum immune response by simultaneously promoting the proliferation of lymphocytes and mononuclear macrophages in the pig body; moreover, the polypeptide provided by the invention can promote the specific immune response of ASFV antigen in the pig body, so that the polypeptide can be used as an effective component of an ASFV subunit vaccine to enhance the immune response of pigs.

The invention discloses an African swine fever virus vaccine. The vaccine is obtained by constructing a recombinant adenovirus vector co-expressed by four antigen genes of an African swine fever virus and packaging the recombinant adenovirus vector through 293TD37 cells. Wherein the four antigen genes of the African swine fever virus are EP402R, EP153R, I177L and K205Rubiqutin respectively. The construction of the recombinant adenovirus vector co-expressed by the four antigen genes of the African swine fever virus mainly comprises the following steps: knocking out E1, E3, E2a and E4 genes of an adenovirus vector through CRISPR / cas9 to construct shuttle plasmids in E1 and E4 regions, and respectively expressing the EP402R, EP153R, I177L and K205Rubiqutin genes by using the shuttle plasmids, thereby obtaining a brand-new adenovirus vector. Compared with a first-generation adenovirus vector, the vector has the advantages that the vector capacity is increased by about 3kb, and the recombinant adenovirus with relatively high titer is obtained by carrying out packaging through a 293TD37 cell line and is used for preparing a recombinant adenovirus vaccine for an African swine fever. According to the African swine fever virus vaccine, the capacity of the adenovirus vector vaccine can be greatly increased, and the specific immune response to the African swine fever virus is enhanced by simultaneously expressing four independent antigens of the African swine fever on one adenovirus vector.

The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E7, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients.

The invention discloses an oral drug delivery system using composite nanomaterials as carriers. The composite nanomaterials HP55 and PBCA are used as shells to coat drug solutions to form nanoparticles. The method adopts the biodegradable and good biocompatibility composite nanometer material as the carrier of the oral medicine, which can improve the bioavailability of the oral medicine. In the field of biomedicine, the nanoparticle can be used for oral delivery of Helicobacter pylori subunit vaccines, which can play a huge role in preventing and treating diseases related to Helicobacter pylori infection.

The present invention relates to a GFP-2 small peptide and its preparation method and application. The small peptide is prepared by the following methods: (1) preparing a brown sugar culture medium and sterilizing it; (2) inoculating with GFP-2 bacteria, glycerol bacteria and Inoculate with LB medium and culture on a shaker; (3) Transfer to brown sugar medium, culture on a shaker, then centrifuge, collect supernatant, and discard bacteria; (4) Salt out to precipitate proteins and small peptides , centrifuge again after salting out, remove the supernatant, and collect the crude protein; (5) Resuspend the crude protein with tris‑HCl, pass the resuspended crude protein through the membrane, and dialyze with tris‑HCl; The filter tube is subjected to ultrafiltration to collect small peptides with a molecular weight of less than 10KD, and the obtained small peptides are cooled and freeze-dried to obtain GFP‑2 small peptides. The prepared small peptide can be used as an adjuvant, which can greatly improve the immune efficacy.